India, Nov. 9 -- Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company developing treatments for cancer and inflammatory diseases, announced Monday that a patient with advanced liver cancer who participated in its completed Phase 2 study of namodenoson has reached ten years of overall survival.
The patient, whose complete response was previously reported, remains cancer-free and in good health.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and often occurs in people with underlying chronic liver disease. Advanced HCC can be difficult to treat, particularly in patients with impaired liver function.
Namodenoson is an investigational, orally available small-molecule drug that selectively bin...